- Home
- BCV vs PRE Comparison
BCV vs PRE Comparison
Compare BCV & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCV | PRE |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.9M | 131.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BCV | PRE |
|---|---|---|
| Price | $22.47 | $15.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 26.3K | ★ 130.7K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $77,079,000.00 |
| Revenue This Year | N/A | $219.28 |
| Revenue Next Year | N/A | $124.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 201.54 |
| 52 Week Low | $14.09 | $3.10 |
| 52 Week High | $18.11 | $17.99 |
Technical Indicators
Market Signals| Indicator | BCV | PRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 60.19 |
| Support Level | $21.96 | $12.93 |
| Resistance Level | $22.83 | $14.50 |
| Average True Range (ATR) | 0.34 | 1.12 |
| MACD | 0.10 | 0.11 |
| Stochastic Oscillator | 79.66 | 93.19 |
Price Performance
Historical ComparisonAbout BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.